Lantern Wealth Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.47M Buy
1,224
+12
+1% +$12.3K 0.67% 39
2026
Q1
$1.11M Buy
1,212
+75
+7% +$76K 0.57% 46
2025
Q4
$1.22M Buy
1,137
+14
+1% +$13.4K 0.65% 38
2025
Q3
$857K Sell
1,123
-281
-20% -$209K 0.45% 55
2025
Q2
$1.09M Buy
+1,404
New +$1.09M 0.65% 44
2024
Q2
Sell
-1,069
Closed -$832K 138
2024
Q1
$832K Sell
1,069
-1
-0.1% -$712 0.58% 51
2023
Q4
$624K Buy
+1,070
New +$625K 0.49% 53

Other funds holding LLY

Lantern Wealth Advisors's LLY Position: Q2 2026 in Review

Lantern Wealth Advisors increased its Eli Lilly (LLY) stake by 0.99% in Q2 2026, buying an estimated $12.3K and bringing the position to 1,224 shares worth $1.47M. The position accounts for 0.67% of the portfolio, ranked #39.

Lantern Wealth Advisors first reported a position in LLY in Q4 2023 and has held it in 7 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Lantern Wealth Advisors held 1,224 shares of Eli Lilly worth $1.47M as of Q2 2026.
  • Lantern Wealth Advisors bought 12 Eli Lilly shares in Q2 2026, an estimated $12.3K.
  • Eli Lilly made up 0.67% of Lantern Wealth Advisors's portfolio in Q2 2026, its #39 holding.
  • Lantern Wealth Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 7 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Lantern Wealth Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.